Matt Hoffman

The task force assessed 6 total interventions, all of which received conditional recommendations aside from cognitive behavioral therapy for insomnia, which was strongly recommended.

"Mind Moments," a podcast from NeurologyLive, brings you an exclusive look into the FDA approval of aducanumab (Aduhelm; Biogen) for the treatment of Alzheimer disease.

Experts in the treatment and management of patients with Alzheimer disease and dementia, including Marwan Sabbagh, MD; Lon Schneider, MD, MS; Anton Porsteinsson, MD; and Robert Howard, MD, MRCPsych, weigh in on the FDA's controversial approval of Biogen's anti-amyloid drug, aducanumab.

The FDA has approved Biogen’s disease-modifying, anti-amyloid agent aducanumab after a tumultuous regulatory journey.

Using the FDA-approved Cefaly device, the TEAM study data suggest that the device can be applied as a safe alternative to pharmacological treatments in the acute treatment of migraine.

An assessment of data from the PROMISE-2 trial suggests that individuals who respond to treatment in the first month are likely to maintain their response through at least 6 months.

Open-label data of concomitant use of CGRP monoclonal antibodies and receptor antagonists suggest that the agents can be safely and effectively combined in the treatment of migraine.

Respondents reported varying levels of comfort regarding the management of migraine during pregnancy, with only half of women’s healthcare providers indicating they conducted counseling on migraine during pregnancy.

"Mind Moments," a podcast from NeurologyLive, brings you an exclusive interview with Barry Hendin, MD.

Identified by Mayo Clinic investigators, the protein-coding gene SERPINA5 was found to be associated with tau expression, characteristic of Alzheimer disease pathology.

Marisa McGinley, DO, from the Mellen Center for Multiple Sclerosis Treatment and Research at Cleveland Clinic, offered her insight into the manual dexterity test and the need to better prognosticate dexterity issues.

Biohaven’s agent is now the first oral CGRP antagonist to be approved for prevention, and the first to be approved for both acute and preventive therapy. It is marketed as Nurtec ODT and is administered in a 75-mg dose.

"Mind Moments," a podcast from NeurologyLive, brings you an exclusive interview with Matthew B. Harms, MD.

Sleep depth was observed to be an independent predictor of heart rate change following seizure for patients with epilepsy.

Improvements in DMTs and management standards appear to have lowered the risk of progression to EDSS scores of 4.0 and 6.0 for those with pediatric-onset disease.

The Epilepsy Digital Experience Navigator, or EDEN, platform, is being developed in tandem with Embleema, with an aim of improving data use and collection for individuals with epilepsy.

"Mind Moments," a podcast from NeurologyLive, brings you an exclusive interview with Elyse Stock, MD, and Thomas Shiovitz, MD.

Two experts in spinal muscular atrophy (SMA) care, Diana Castro, MD, and Garey H. Noritz, MD, offer tips and demonstrations for screening and diagnosing SMA via telehealth, and they outline resources provided by Cure SMA for families and clinicians who suspect, or have a patient with a diagnosis of, SMA.

The chief scientific officer of the Parkinson’s Foundation and adjunct associate professor in the Department of Neuroscience and Physiology at New York University School of Medicine discussed the adoption of telemedicine in Parkinson disease care.

"Mind Moments," a podcast from NeurologyLive, brings you exclusive interviews with Stephanie J. Nahas, MD; Bruce Cree, MD, PhD, MAS; Sana Somani, MD, MBBS; Hubert Fernandez, MD; Daniel Ontaneda, MD, PhD; and Richard Gershon, PhD.

Just weeks after receiving an EU marketing authorization, the FDA has issued a complete response letter to Biogen for its sBLA related to the subcutaneous administration of natalizumab (Tysabri).

Formerly known as BIIB067, the antisense oligonucleotide is expected to be available for rapidly progressing patients in mid-July 2021, and for the broader SOD1-ALS population in the fall.

"Mind Moments," a podcast from NeurologyLive, brings you an exclusive interview with Daniel Claassen, MD, MS.

The MTB is built to safely, remotely, and effectively collect data from assessments that measure the executive function, language, memory, and processing speed of adults, and can be captured via smartphone.

In an AAN plenary talk, Mark H. Tuszynski, MD, PhD, detailed the work he and colleagues have done to push stem cell therapy from the lab to the clinic to improve care for spinal cord injury.

Aducanumab currently sits before the FDA for review for the treatment of Alzheimer disease, with a PDUFA date set for June 7, 2021.

Data from a cohort of more than 900 individuals suggest that while total tau can add cross-sectional value in certain contexts, neurofilament light served better for prognostication of cognitive decline and imaging changes.

The 2021 AAN Annual Meeting will be held virtually from April 17-22. Follow along with coverage from NeurologyLive, including expert interviews and session recaps.

"Mind Moments," a podcast from NeurologyLive, brings you an exclusive interview with Bhooma Aravamuthan, MD, DPhil.

A case report showed 1 patient in the vaccine arm developed Guillain-Barré syndrome, though 1 in the placebo arm also developed the syndrome, implying coincidence rather than causation.